Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
William Grady MD

William M. Grady MD

Professor, Division of Translational Sciences and Therapeutics, and Medical Director, Gastrointestinal Cancer Prevention Program, Fred Hutchinson Cancer Center; Rodger C. Haggitt Professor, Division of Gastroenterology, University Washington School of Medicine, Seattle Washington

Dr. Grady is a molecular biologist and board-certified gastroenterologist. He is an independent NIH funded PI with >20 years of experience in translational research related to gastrointestinal cancer.

He is Head of the GI Cancer Program at the Seattle Cancer Care Alliance, a Co-Head of the GI Cancer Program of the Fred Hutchinson Cancer Center (FHCC)/University of Washington Comprehensive Cancer Center and the Director of Translational Research for the Gastroenterology Division at the University of Washington. Furthermore, Dr. Grady, in his role of a practicing gastroenterologist, manages patients with a variety of gastrointestinal diseases including Barretts esophagus, colon polyps and gastrointestinal cancer.

He is the Medical Director of the GI Cancer Prevention Program Clinic at the Seattle Cancer Care Alliance, which specializes in the care of individuals who have cancer family syndromes, including Lynch syndrome and polyposis syndromes.


Dr. Grady is a scientific advisory board member for Freenome, Guardant Health, and SEngine and a consultant for DiaCarta, Natera, Guidepoint, Karius and GLG; he receives research support from Tempus and LucidDx.